Summit Therapeutics Inc. (SMMT)

NASDAQ: SMMT · IEX Real-Time Price · USD
4.140
+0.390 (10.40%)
At close: Mar 28, 2024, 4:00 PM
4.150
+0.010 (0.24%)
After-hours: Mar 28, 2024, 4:49 PM EDT
10.40%
Market Cap 2.63B
Revenue (ttm) n/a
Net Income (ttm) -614.93M
Shares Out 701.66M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,606,262
Open 4.210
Previous Close 3.750
Day's Range 4.100 - 4.640
52-Week Range 1.300 - 5.220
Beta -1.21
Analysts Strong Buy
Price Target 8.00 (+93.24%)
Earnings Date May 9, 2024

About SMMT

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes c... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 105
Stock Exchange NASDAQ
Ticker Symbol SMMT
Full Company Profile

Financial Performance

Financial numbers in GBP Financial Statements

Analyst Forecast

According to one analyst, the rating for SMMT stock is "Strong Buy" and the 12-month stock price forecast is $8.0.

Price Target
$8.0
(93.24% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced promising data for its novel, potential first-in-class investigational bisp...

6 days ago - Business Wire

Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecifi...

14 days ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT

NEW YORK , March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT).  Such investors are advis...

16 days ago - PRNewsWire

Shareholders that lost money on Summit Therapeutics Inc. (SMMT) should contact Levi & Korsinsky about Securities Fraud Investigation - SMMT

NEW YORK, NY / ACCESSWIRE / March 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning poss...

22 days ago - Accesswire

Lost Money on Summit Therapeutics Inc.(SMMT)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

NEW YORK, NY / ACCESSWIRE / March 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning poss...

22 days ago - Accesswire

Summit Therapeutics Being Investigated on Behalf of Summit Therapeutics Inc. Investors. Contact Levi & Korsinsky For Details.

NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning poss...

23 days ago - Accesswire

Lost Money on Summit Therapeutics Inc.(SMMT)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning poss...

23 days ago - Accesswire

Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the Barclays 26th Annual Global ...

23 days ago - Business Wire

Shareholders that lost money on Summit Therapeutics Inc.(SMMT) should contact Levi & Korsinsky about Securities Fraud Investigation - SMMT

NEW YORK, NY / ACCESSWIRE / February 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning ...

4 weeks ago - Accesswire

Levi & Korsinsky Announces an Investigation on Behalf of Summit Therapeutics Inc. (SMMT) Shareholders Who May Have Been Affected by Fraud

NEW YORK, NY / ACCESSWIRE / February 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning ...

4 weeks ago - Accesswire

Summit Therapeutics Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - SMMT

NEW YORK, NY / ACCESSWIRE / February 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning ...

4 weeks ago - Accesswire

ATTENTION Summit Therapeutics Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights

NEW YORK, NY / ACCESSWIRE / February 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning ...

4 weeks ago - Accesswire

SMMT ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Summit Therapeutics Inc. Shareholders Who Lost Money

NEW YORK, NY / ACCESSWIRE / February 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning ...

4 weeks ago - Accesswire

Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

NEW YORK--(BUSINESS WIRE)---- $SMMT #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Summit Therapeutics Inc. (“Summi...

4 weeks ago - Business Wire

Levi & Korsinsky Reminds Shareholders of an Investigation into Summit Therapeutics Inc. (SMMT) Regarding Potential Securities Fraud Allegations

NEW YORK, NY / ACCESSWIRE / February 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning ...

4 weeks ago - Accesswire

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for ...

5 weeks ago - Business Wire

Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024

MIAMI, Fla.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth quarter and full year 2023 financia...

6 weeks ago - Business Wire

Summit Therapeutics to Host Fourth Quarter & Full Year 2023

MIAMI, Fla.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth quarter and full year 2023 financia...

6 weeks ago - Business Wire

Summit Therapeutics to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at Oppenheimer's 34th Annual Health...

7 weeks ago - Business Wire

Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced substantial updates to the promising development of ivonescimab, as well as...

2 months ago - Business Wire

Summit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 42nd Annual J.P...

3 months ago - Business Wire

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023

MENLO PARK, Calif.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational prog...

5 months ago - Business Wire

Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical Development

MENLO PARK, Calif.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Laura Chow, MD, has joined Summit Therapeutics as Senior ...

5 months ago - Business Wire

Ivonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023

Potential First-in-Class Tetravalent Bispecific Antibody Demonstrates Enhanced Binding in the Simultaneous Presence of PD-1 & VEGF Cooperative Binding of Ivonescimab Enables Higher Avidity in the Tumo...

5 months ago - PRNewsWire

Summit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023

MENLO PARK, Calif.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its third quarter 2023 financial result...

5 months ago - Business Wire